{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:29:01Z","timestamp":1773275341872,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.4158\/ep.6.5.401","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:37:07Z","timestamp":1365205027000},"page":"401-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of Thyroid Cancer: Radioiodine Ablation, \u201cStunning,\u201d and Treatment of Thyroglobulin-Positive, 131I Scan-Negative Patients"],"prefix":"10.1016","volume":"6","author":[{"given":"James R.","family":"Hurley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.6.5.401_bb0010","series-title":"Diagnostic Nuclear Medicine","first-page":"959","article-title":"Treatment of thyroid cancer with radioiodine (131I). In","author":"Hurley","year":"1996"},{"key":"10.4158\/EP.6.5.401_bb0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [published erratum appears in Am J Med. 1995;98:215]","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am J Med"},{"key":"10.4158\/EP.6.5.401_bb0020","first-page":"1132","article-title":"Radioiodine-131 therapy for well-differentiated thyroid cancer\u2014a quantitative radiation dosimetric approach: outcome and validation in 85 patients","volume":"33","author":"Maxon","year":"1992","journal-title":"J Nucl Med"},{"key":"10.4158\/EP.6.5.401_bb0025","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O","article-title":"Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma","volume":"77","author":"Bal","year":"1996","journal-title":"Cancer"},{"key":"10.4158\/EP.6.5.401_bb0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0889-8529(18)30310-4","article-title":"Papillary thyroid carcinoma","volume":"19","author":"Hay","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP.6.5.401_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/thy.1994.4.49","article-title":"Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131","volume":"4","author":"Park","year":"1994","journal-title":"Thyroid"},{"key":"10.4158\/EP.6.5.401_bb0040","first-page":"1546","article-title":"Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma","volume":"39","author":"Muratet","year":"1998","journal-title":"J Nucl Med"},{"key":"10.4158\/EP.6.5.401_bb0045","first-page":"1362","article-title":"Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma","volume":"38","author":"Muratet","year":"1997","journal-title":"J Nucl Med"},{"key":"10.4158\/EP.6.5.401_bb0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00006231-199706000-00002","article-title":"74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer","volume":"18","author":"McDougall","year":"1997","journal-title":"Nucl Med Commun"},{"key":"10.4158\/EP.6.5.401_bb0055","first-page":"1888","article-title":"Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels","volume":"28","author":"Pacini","year":"1987","journal-title":"J Nucl Med"},{"key":"10.4158\/EP.6.5.401_bb0060","first-page":"1488","article-title":"Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan","volume":"80","author":"Pineda","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.6.5.401_bb0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.1997.7.273","article-title":"131I therapy for elevated thyroglobulin levels","volume":"7","author":"Schlumberger","year":"1997","journal-title":"Thyroid"},{"key":"10.4158\/EP.6.5.401_bb0070","first-page":"98","article-title":"Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer","volume":"79","author":"Ozata","year":"1994","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/WFMMMEG1560R7RY6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:33Z","timestamp":1761514833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20420014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["S1530891X20420014"],"URL":"https:\/\/doi.org\/10.4158\/ep.6.5.401","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Thyroid Cancer: Radioiodine Ablation, \u201cStunning,\u201d and Treatment of Thyroglobulin-Positive, 131I Scan-Negative Patients","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.6.5.401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}